$ZLCS Recent News Zalicus to discontinue rheumat
Post# of 94264
Posted On: 11/11/2013 5:17:29 PM
$ZLCS Recent News
Zalicus to discontinue rheumatoid arthritis drug 10:38 a.m. Sept. 10, 2012 - MarketWatch.com
Pfizer, Affymetrix weigh on drug stocks 2:04 p.m. July 7, 2011 - Val Brickates Kennedy
Tuesday’s biggest advancing and declining stocks 2:35 p.m. July 5, 2011 - Kate Gibson
Drug stocks sluggish; Zalicus jumps 12:17 p.m. July 5, 2011 - Val Brickates Kennedy
Zalicus jumps 10% on stock rating 9:18 a.m. July 5, 2011 - Val Brickates Kennedy
5 reasons I can’t sell B. of A. — should you buy? 8:42 a.m. April 21, 2011 - Jeff Reeves
10 expert stock picks for 2011 12:02 a.m. Jan. 5, 2011 - Jeff Reeves
UPDATE: Oppenheimer Downgraded Zalicus 2:49 p.m. Today - benzinga.com
Intel Buys ‘Kno’ to Reinforce Education Laptops Sideline and 2 Other Hot Stocks to Watch 11:35 a.m. Today - Wall St. Cheat Sheet
Zalicus Plunges on Pain Drug Blowup 11:30 a.m. Today - TheStreet.com
Zalicus' Z160 Fails, What Now? 11:05 a.m. Today - Seeking Alpha
Zalicus: Investors Get Sucker Punched 10:58 a.m. Today - Seeking Alpha
UPDATE: Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic Neuropathic Pain 7:32 a.m. Today - benzinga.com
Key Issues Surrounding The Zalicus Catalyst Trade 8:56 a.m. Nov. 8, 2013 - Seeking Alpha
Clues And Controversy: Why Zalicus Shares Could Be Set For A Rally 9:08 a.m. Nov. 6, 2013 - Seeking Alpha
Where Is Zalicus After Trial Results? 2:06 p.m. Nov. 5, 2013 - Seeking Alpha
Recent FDA News Makes A Zalicus Trade Look Even More Compelling 4:27 a.m. Oct. 29, 2013 - Seeking Alpha
Zalicus: An Upcoming Catalyst With Huge Potential 10:06 a.m. Oct. 24, 2013 - Seeking Alpha
4 Biotechnology Stocks With Room To Climb 8:10 a.m. Oct. 15, 2013 - Seeking Alpha
A High Risk-High Reward Biopharma With Two Pending Catalysts 7:16 a.m. Oct. 4, 2013 - Seeking Alpha
Zalicus Shares Nosedive Following News of 1-for-6 Reverse Split 2:57 p.m. Oct. 2, 2013 - benzinga.com
Zalicus Is A Promising Biotech With Echoes Of Acadia Pharmaceuticals 9:25 a.m. Sept. 20, 2013 - Seeking Alpha
AcelRx Pharmaceuticals To Submit NDA By End Of September, May Be Acquired Soon 6:55 a.m. Sept. 20, 2013 - Seeking Alpha
10-Q: ZALICUS INC. 3:11 p.m. Aug. 5, 2013 - Edgar Online - (EDG = 10Q, 10K)
For Zalicus, Z160 Data In October Could Be Huge 11:22 a.m. Aug. 1, 2013 - Seeking Alpha
Zalicus Announces Advancing Clinical Development of Z944 5:38 a.m. June 4, 2013 - benzinga.com
Zalicus Awaiting Data On Potential New Pain Medication 7:19 a.m. May 23, 2013 - Seeking Alpha
ZLCS, CLRX, DSCO and GALE added to NASDAQ Active Stock Watch List at GSR 10:20 a.m. Today - ACCESSWIRE
Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic Neuropathic Pain 8:30 a.m. Today - BusinessWire
Closing of Over-Allotment Options, Receiving Orphan Drug Designations, Release of Clinical Data, and Obtaining Important Patents - Research Report on Galena, Zalicus, Infinity, Stemline and Insmed 8:00 a.m. Nov. 5, 2013 - PR Newswire
Zalicus Reports Financial Results for the Third Quarter 2013 7:30 a.m. Nov. 4, 2013 - BusinessWire
Zalicus Announces Positive Results of Z944 Phase 1b Clinical Study in Pain 7:30 a.m. Nov. 1, 2013 - BusinessWire
Under The Radar Big Pharma Partnership Opportunity for Zalicus,Targacept and ACADIA 4:17 a.m. Oct. 31, 2013 - ACCESSWIRE
Healthcare Companies Report Quarterly Financial Results - Research Report on Celgene, Natus, Merit Medical, Invacare, and Zalicus 8:00 a.m. Oct. 30, 2013 - PR Newswire
Zalicus Regains Compliance with Nasdaq Listing Requirements 6:30 a.m. Oct. 15, 2013 - BusinessWire
Zalicus Announces 1-for-6 Reverse Stock Split 3:01 p.m. Oct. 2, 2013 - BusinessWire
Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus 7:00 a.m. Oct. 2, 2013 - PR Newswire
TSLA, AGNC, GERN and ZLCS added to Nasdaq Active Stock Watch List at GSR 8:05 a.m. Oct. 1, 2013 - ACCESSWIRE
Zalicus' Z160 Receives Orphan Drug Designation for the Management of Postherpetic Neuralgia 8:44 a.m. Sept. 27, 2013 - BusinessWire
Zalicus Initiates Phase 1b Clinical Study of Z944, Its Novel, Oral, T-type Calcium Channel Blocker, for the Treatment of Pain 6:30 a.m. Sept. 9, 2013 - BusinessWire
Osmotica Pharmaceutical Corp. Announces the Appointment of Gene Wright, Pharm.D., Ph.D. as Vice President, Head of Global Clinical Development 8:00 a.m. Sept. 6, 2013 - BusinessWire
Zalicus to Present at the Rodman & Renshaw 15th Annual Global Investment Conference 7:30 a.m. Sept. 3, 2013 - BusinessWire
Zalicus Completes Patient Enrollment in Two Phase 2 Clinical Studies of Z160 for Chronic Neuropathic Pain 7:00 a.m. Sept. 3, 2013 - BusinessWire
Zalicus Reports Financial Results for the Second Quarter 2013 6:30 a.m. Aug. 1, 2013 - BusinessWire
Zalicus Publishes Data on Selective Estrogen Receptor Modulators for the Treatment of Infectious Disease 3:01 p.m. June 19, 2013 - BusinessWire
Zalicus Advancing Clinical Development of Z944, Its Novel, Oral, T-Type Calcium Channel Blocker, for the Treatment of Pain 6:30 a.m. June 4, 2013 - BusinessWire
Zalicus to Present at the Jefferies 2013 Global Healthcare Conference 7:30 a.m. May 29, 2013 - BusinessWire
Zalicus to discontinue rheumatoid arthritis drug 10:38 a.m. Sept. 10, 2012 - MarketWatch.com
Pfizer, Affymetrix weigh on drug stocks 2:04 p.m. July 7, 2011 - Val Brickates Kennedy
Tuesday’s biggest advancing and declining stocks 2:35 p.m. July 5, 2011 - Kate Gibson
Drug stocks sluggish; Zalicus jumps 12:17 p.m. July 5, 2011 - Val Brickates Kennedy
Zalicus jumps 10% on stock rating 9:18 a.m. July 5, 2011 - Val Brickates Kennedy
5 reasons I can’t sell B. of A. — should you buy? 8:42 a.m. April 21, 2011 - Jeff Reeves
10 expert stock picks for 2011 12:02 a.m. Jan. 5, 2011 - Jeff Reeves
UPDATE: Oppenheimer Downgraded Zalicus 2:49 p.m. Today - benzinga.com
Intel Buys ‘Kno’ to Reinforce Education Laptops Sideline and 2 Other Hot Stocks to Watch 11:35 a.m. Today - Wall St. Cheat Sheet
Zalicus Plunges on Pain Drug Blowup 11:30 a.m. Today - TheStreet.com
Zalicus' Z160 Fails, What Now? 11:05 a.m. Today - Seeking Alpha
Zalicus: Investors Get Sucker Punched 10:58 a.m. Today - Seeking Alpha
UPDATE: Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic Neuropathic Pain 7:32 a.m. Today - benzinga.com
Key Issues Surrounding The Zalicus Catalyst Trade 8:56 a.m. Nov. 8, 2013 - Seeking Alpha
Clues And Controversy: Why Zalicus Shares Could Be Set For A Rally 9:08 a.m. Nov. 6, 2013 - Seeking Alpha
Where Is Zalicus After Trial Results? 2:06 p.m. Nov. 5, 2013 - Seeking Alpha
Recent FDA News Makes A Zalicus Trade Look Even More Compelling 4:27 a.m. Oct. 29, 2013 - Seeking Alpha
Zalicus: An Upcoming Catalyst With Huge Potential 10:06 a.m. Oct. 24, 2013 - Seeking Alpha
4 Biotechnology Stocks With Room To Climb 8:10 a.m. Oct. 15, 2013 - Seeking Alpha
A High Risk-High Reward Biopharma With Two Pending Catalysts 7:16 a.m. Oct. 4, 2013 - Seeking Alpha
Zalicus Shares Nosedive Following News of 1-for-6 Reverse Split 2:57 p.m. Oct. 2, 2013 - benzinga.com
Zalicus Is A Promising Biotech With Echoes Of Acadia Pharmaceuticals 9:25 a.m. Sept. 20, 2013 - Seeking Alpha
AcelRx Pharmaceuticals To Submit NDA By End Of September, May Be Acquired Soon 6:55 a.m. Sept. 20, 2013 - Seeking Alpha
10-Q: ZALICUS INC. 3:11 p.m. Aug. 5, 2013 - Edgar Online - (EDG = 10Q, 10K)
For Zalicus, Z160 Data In October Could Be Huge 11:22 a.m. Aug. 1, 2013 - Seeking Alpha
Zalicus Announces Advancing Clinical Development of Z944 5:38 a.m. June 4, 2013 - benzinga.com
Zalicus Awaiting Data On Potential New Pain Medication 7:19 a.m. May 23, 2013 - Seeking Alpha
ZLCS, CLRX, DSCO and GALE added to NASDAQ Active Stock Watch List at GSR 10:20 a.m. Today - ACCESSWIRE
Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic Neuropathic Pain 8:30 a.m. Today - BusinessWire
Closing of Over-Allotment Options, Receiving Orphan Drug Designations, Release of Clinical Data, and Obtaining Important Patents - Research Report on Galena, Zalicus, Infinity, Stemline and Insmed 8:00 a.m. Nov. 5, 2013 - PR Newswire
Zalicus Reports Financial Results for the Third Quarter 2013 7:30 a.m. Nov. 4, 2013 - BusinessWire
Zalicus Announces Positive Results of Z944 Phase 1b Clinical Study in Pain 7:30 a.m. Nov. 1, 2013 - BusinessWire
Under The Radar Big Pharma Partnership Opportunity for Zalicus,Targacept and ACADIA 4:17 a.m. Oct. 31, 2013 - ACCESSWIRE
Healthcare Companies Report Quarterly Financial Results - Research Report on Celgene, Natus, Merit Medical, Invacare, and Zalicus 8:00 a.m. Oct. 30, 2013 - PR Newswire
Zalicus Regains Compliance with Nasdaq Listing Requirements 6:30 a.m. Oct. 15, 2013 - BusinessWire
Zalicus Announces 1-for-6 Reverse Stock Split 3:01 p.m. Oct. 2, 2013 - BusinessWire
Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus 7:00 a.m. Oct. 2, 2013 - PR Newswire
TSLA, AGNC, GERN and ZLCS added to Nasdaq Active Stock Watch List at GSR 8:05 a.m. Oct. 1, 2013 - ACCESSWIRE
Zalicus' Z160 Receives Orphan Drug Designation for the Management of Postherpetic Neuralgia 8:44 a.m. Sept. 27, 2013 - BusinessWire
Zalicus Initiates Phase 1b Clinical Study of Z944, Its Novel, Oral, T-type Calcium Channel Blocker, for the Treatment of Pain 6:30 a.m. Sept. 9, 2013 - BusinessWire
Osmotica Pharmaceutical Corp. Announces the Appointment of Gene Wright, Pharm.D., Ph.D. as Vice President, Head of Global Clinical Development 8:00 a.m. Sept. 6, 2013 - BusinessWire
Zalicus to Present at the Rodman & Renshaw 15th Annual Global Investment Conference 7:30 a.m. Sept. 3, 2013 - BusinessWire
Zalicus Completes Patient Enrollment in Two Phase 2 Clinical Studies of Z160 for Chronic Neuropathic Pain 7:00 a.m. Sept. 3, 2013 - BusinessWire
Zalicus Reports Financial Results for the Second Quarter 2013 6:30 a.m. Aug. 1, 2013 - BusinessWire
Zalicus Publishes Data on Selective Estrogen Receptor Modulators for the Treatment of Infectious Disease 3:01 p.m. June 19, 2013 - BusinessWire
Zalicus Advancing Clinical Development of Z944, Its Novel, Oral, T-Type Calcium Channel Blocker, for the Treatment of Pain 6:30 a.m. June 4, 2013 - BusinessWire
Zalicus to Present at the Jefferies 2013 Global Healthcare Conference 7:30 a.m. May 29, 2013 - BusinessWire
(0)
(0)